Drug firm Dr Reddy's Laboratories today said it has launched levocetirizine tablets, which are used for relieving allergies, in the American market.
The US Food and Drug Administration approved its abbreviated new drug application for levocetirizine tablets on February 24, Dr Reddy's Laboratories said in a filing to the Bombay Stock Exchange (BSE).
The product, which is a generic equivalent of UCB's Xyzal tablets, is used to treat or prevent symptoms of allergies. It is also used to help reduce itchy skin rash and hives.
The company has launched the tablet in 5 mg strength in the US market. The tablets are available in 90 count bottles.
According IMS Health Sales data, levocetirizine tablets posted sales of about $238 million in the US market for the 12-month period ended September 30, 2010.
Shares of the company were trading at Rs 1,552.50 on the BSE, up 0.19% from the previous close.